Azetukalner - Xenon Pharmaceuticals
Alternative Names: 1OP 2198; Encukalner; VRX 621698; XEN-1101; XPF-008Latest Information Update: 11 Dec 2024
Price :
$50 *
At a glance
- Originator Bausch Health Companies
- Developer Icahn School of Medicine at Mount Sinai; Xenon Pharmaceuticals
- Class Antidepressants; Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action KCNQ potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Partial epilepsies; Tonic-clonic epilepsy
- Phase II Major depressive disorder
- No development reported Epilepsy
Most Recent Events
- 06 Dec 2024 Updated efficacy data from the phase II X-TOLE trial in Focal onset seizures released by Xenon Pharmaceuticals
- 28 Nov 2024 No recent reports of development identified for phase-I development in Major depressive disorder in Canada (PO, Capsule)
- 07 Nov 2024 Xenon completes a phase II trial in Major depressive disorder in USA (PO) (NCT04827901)